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Abstract
Background: The eSVS® external venous nitinol mesh (Kips Bay Medical, Minneapolis, USA) was designed to
improve long-term patency of coronary saphenous vein grafts (SVG) by preventing pressure-induced wall stress and
reactive neo-intimal hyperplasia. We present one-year-patency rates of meshed SVGs assessed by coronary computed
tomographic angiography (cCTA).
Patients and Methods: Data from consecutive patients receiving an eSVS® meshed coronary bypass SVG from
06/2010 to 06/2011 were prospectively collected and analysed post-hoc. Patient characteristics, coronary artery
disease, SVG quality, surgery (including number of anastomoses and transit time flow-measurement: TTFM),
postoperative course and graft patency by cCTA were recorded. Potential risk factors for meshed graft occlusion were
evaluated.
Results: 22 patients received an eSVS® mesh (18 isolated CABG, 4 combined with aortic valve replacement). Three
patients died prior to the one-year follow-up and were excluded. All 19 surviving patients (mean age 70.4 ± 9.5 years,
3 female) completed a cCTA of all grafts at 12 ± 0.1 months after surgery including 21 meshed SVGs (33 distal
anastomoses), 7 unmeshed SVGs (13 distal anastomoses) and 22 arterial grafts (30 distal anastomoses).
Mesh application was safe with patent grafts (by intraoperative TTFM) and perioperative course uneventful
in all patients. The average graft/anastomosis number per patient was 2.6 ± 0.5/3.7 ± 0.8. Patency was
unrestricted in all arterial and unmeshed SVGs (cCTA). Meshed SVG patency was 85 % (n = 28/33) for distal
anastomoses and 76 % (n = 16/21) among meshed SVGs. Four SVGs with single distal anastomosis to the
right coronary were completely occluded. One sequential graft to the left coronary was occluded between
proximal and first distal anastomosis (see Fig. 1). Patency was independent of target site, coronary run-off,
SVG quality and sequential distal grafting. All patients were asymptomatic.
Conclusions: The overall one-year patency rate of eSVS® meshed SVGs/anastomoses was 76 %/85 %. Surgical
implantation is safe independently of target site, run-off, vein quality and sequential distal anastomoses. However, graft
patency of meshed veins (76 %) was inferior to non-meshed (100 %) or arterial grafts (100 %). Thus our mid-term data
do not sustain the concept of improving vein graft patency by external reinforcing with the eSVS® mesh.
Further long-term follow-up is warranted.
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Background
The use of autologous saphenous vein grafts (SVG) for
coronary artery bypass grafting (CABG) has been
adopted all over the world. However, intermediate- and
long-term patency of SVGs is inferior to arterial grafts
as to reactive intimal hyperplasia with luminal restriction
and progressive atherosclerotic SVG disease with subse-
quent thrombotic graft occlusion [1, 2]. Despite the
current tendency of favoring totally arterial revasculari-
sation a lack of suitable graft material and the knowledge
about favorable patency of SVGs in coronary stenosis <
90 % still make the use of SVGs essential [3, 4].
The eSVS® mesh (Kips Bay Medical, Inc., Minneapolis,
USA) is a flexible extravascular nickel-titanium mesh de-
signed to reinforce SVGs exposed to the higher arterial
pressure in CABG [5]. Its preventive effect on reactive
intimal hyperplasia was demonstrated in primates and
after CE certification in May 2010 the device was re-
leased for implantation in humans [6]. Although long-
term patency is not yet available first safety reports and
short-term results have been recently published [7, 8].
Genoni et al. stated a safe application of the device in 20
patients operated off-pump to receive an eSVS® mesh
supported SVG to the right coronary artery [7]. The pa-
tency rate 5 days after surgery was 95 %. Klima et al.
recently published a 7-months cCTA follow-up in 12 pa-
tients after on-pump non-sequential eSVS® mesh sup-
ported SVG to both sided coronaries with a patency rate
of 92 % [8]. Both studies describe a safe application of
the eSVS® mesh and reveal satisfying patency rates when
compared to those of non-meshed SVGs [1].
This study presents for the first time one-year patency
rates of eSVS® mesh supported SVGs in 19 patients in-
cluding on- and off-pump revascularisation of the left
and right coronary system, sequential and single distal
anastomoses and provides information about the vein
harvest technique, site, quality and the coronary run-off.
Methods
Patients and baseline characteristics, data collection
From June 2010 until June 2011, 22 consecutive patients
receiving an eSVS® (Kips Bay Medical, Inc., Minneapolis,
USA) meshed saphenous vein coronary bypass graft (SVG)
wereprospectivelyenrolledanddataanalyzedpost-hoc.Graft
patency as the main endpoint was evaluated by cCTA
one year after surgery. Potential risk factors for graft
occlusion were statistically analyzed as secondary end-
points. 3 patients were ruled out due to non-device related
in-hospital cardiac (n = 1) or post-discharge non-cardiac
death prior to the scheduled 1-year follow-up.
The data collection (Tables 1, 2 and 3) consisted of pa-
tients’ characteristics (including NYHA class), coronary
artery disease and left ventricular function (LVEF), sur-
gery (including perfusion-type, native coronary run-off,
technique of proximal anastomosis, graft harvest tech-
nique / site and quality, mesh sizes, intra-operative transit
time flow-measurement, device related complications)
and postoperative follow-up (including MACCE). Clinical
and cCTA follow-up was provided one year after surgery.
The device: the eSVS® mesh
TheeSVS®mesh (External SaphenousVein SupportDevice,
KipsBayMedical,Inc.,Minneapolis,USA)isahighlyflexible,
semi-compliant, kink-resistant extravascular tubular pros-
thesis fabricatedofknittednickel-titanium(nitinol)wirede-
signed to improve autologous vein graft patency in human
CABG.ThedevicewasCEcertifiedinMay2010andisreleased
forCABGinhumanseversince.
Anesthesia, Surgery and Procedural Characteristics
All patients received general anesthesia and continuous
monitoring by 2-lead electrocardiography (II, V5), pulse-
oxymetry and invasive measurement of arterial blood and
central venous pressure. Transesophageal echocardiog-
raphy (TEE) was performed throughout the procedure.
Antibiotic prophylaxis (Cefuroxim) was administrated
within 30 min prior to skin incision.
All patients were subjected to coronary artery bypass
grafting (CABG) with the following revascularisation
Fig. 1 Coronary Computed Tomographic Angiography of a Partially
Occluded Meshed SVG cCTA three-dimensional reconstruction
showing a partially occluded eSVS® supported SVG between its
proximal aortic and first distal sequential anastomosis (arrow). However,
a contrast filling of the distal SVG between the first and last distal
sequential anastomosis confirms patency in this section of the SVG
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techniques: Off-pump CABG (OPCAB) and conventional
(ECC)/minimal extra corporeal circulation (MECC). Each
patient received one eSVS® meshed SVG either to the left
or right coronary system grafted either to one single cor-
onary vessel (one single distal anastomosis) or to two or
more coronaries (sequential distal anastomoses). The tar-
get vessel was selected individually to cover all aspects of
contemporary revascularisation (left/right sided, single/se-
quential grafts) in this patient group. Decision was based
on preoperative angiography and intraoperative assess-
ment of the target vessels. A stenosis of > 75 % was con-
sidered indispensable for being grafted. The left anterior
descending artery (LAD) was routinely grafted using the
left internal mammary artery (LIMA). Coronary run-off
was classified as poor (calcified vessel AND diameter ≤
1.5 mm), moderate (calcified vessel OR diameter ≤
1.5 mm) or good (not calcified vessel AND diameter >
1.5 mm). The residual coronaries with significant stenosis
(>75 %) were grafted using the left or right internal mam-
mary artery (LIMA or RIMA), the radial artery or an
unmeshed SVG.
Saphenous vein harvesting was routinely performed
endoscopically by an experienced resident (>100 harvests)
using the ClearGlide (Sorin, Milano, Italy) endoscopic har-
vest system. A preoperative duplex sonographic vein map-
ping allowed choosing the harvest site (lower leg or thigh)
with the best vein quality. In case of harvesting multiple
vein grafts the segment with the superior quality with
regards to diameter, lack of varicosis and blow-outs was
reserved for meshing. In two cases of absent great saphe-
nous veins (magna) after stripping the minor saphenous
vein (parva) was harvested in an open technique with skin
Table 1 Patients’ characteristics, surgery, follow-up and mortality
Patients (n) exclusive 3 non-device related deaths 19
Gender (n; male) 16
Age (years; mean ± std; min.-max.) 70.4 ± 9.5 (51–81)
Body weight (kg; mean ± std) 80.1 ± 15.0
Bodymassindex (kg/m2; mean ± std) 28.2 ± 5.3
NYHA / CCS classification (n; %) NYHA CCS
I 13 (68.4 %) 2 (10.5 %)
II 4 (21.1 %) 10 (52.7 %)
III 2 (10.5 %) 5 (26.3 %)
IV 0 2 (10.5 %)
Left ventricular ejection fraction
(%; mean ± std)
49 ± 11
CAD in 1° relative (n; %) 17 (89.5 %)
Arterial hypertension (n; %) 18 (94.7 %)
Diabetes (n; %; on insuline/oral
antidiabetics/diet)
0 (0 %) / 2 (10.5 %)/6 (31.5 %)
Dyslipidemia (n; %) 16 (84.2 %) + 1 (5.3 %) unknown
Smoking (n; %; current/former/never) 2 (10.5 %)/13 (68.4 %)/4 (21.1 %)
Previous myocardial infarction (n; %) 13 (68.4 %) + 5 (26.3 %)
no + 1 (5.3 %) unknown
Previous cerebrovascular event (n; %) 2 (10.5 %) (TIA only)
Previous CABG (n; %) 0 (0 %)
Revascularisation (n;%; OPCAB/ECC/MECC) 11 (57.9 %)/5 (26.3 %)/3 (15.8 %)
Extracorporeal circulation time
(min; mean ± std)1)
113.9 ± 35.5 (n = 8)
Cross clamp time (min; mean ± std)1) 79.9 ± 25.3 (n = 8)
Days on intensive care unit (mean ± std) 2.3 ± 1.3
In-hospital days (mean ± std) 10.3 ± 4.7
Directly device-related complications (n) 0
MACCE (n; %) 1 (5.3 %) (Stroke with paraparesis,
complete remission)
NYHA: New York Heart Association, CCS: Canadian Cardiovascular Society, CAD: Coronary arterial disease, TIA: Transient ischemic attack, CABG: Coronary artery
bypass grafting, OPCAB: Off-pump coronary artery bypass, ECC: Extracorporeal circulation, MECC: Minimal extracorporeal circulation, MACCE: Major adverse cardiac
and cerebrovascular event, 1) including concomitant aortic valve replacement
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bridging. Prior to meshing all side branches were ligated
using Prolene 6/0 and residual branch stump tissue
resected in order not to provoke intraluminal restriction
inside the mesh. Mesh deployment was provided as previ-
ously described [5]. Briefly, the appropriate mesh size (3.5,
4.0 or 4.5 mm) was determined by the provided measuring
tool. Graft diameters > 7 mm and < 3.6 mm as well as a
double wall thickness >1.4 mm were contraindications to
apply the eSVS® mesh. The mesh was attached to the SVG
by fibrin tissue glue (Tisseel, Baxter, Vienna, Austria).
Both its distal and proximal end was bevelled obliquely
and incised at the heel for a few millimetres to provide a
cobrahead shape of the graft allowing an unrestricted flow
across the anastomosis [5, 9]. In situ graft flows were
Table 2 Distal anastomoses, transit time flow-measurement (TTFM) and one-year graft patency by cCTA
Graft Distal Anastomosis Number (n) Mean Flow by TTFM (ml/min) Pulsatility Index (TTFM) Patent Grafts (n) Occluded Grafts (n)
Left Coronary System
LIMA Single 15 40 ± 32.4 2.0 ± 0.6 15 0
Jump 21) 39 ± 0.0 2.2 ± 0.8 2 0
RIMA Single 2 58 ± 14.1 1.4 ± 0.6 2 0
Jump 22) 29 ± 8.5 1.3 ± 0.4 2 0
RADIAL A. Single 1 19 1.2 1 0
SVG UNMESHED Jump 43) 37 ± 21.1 2.4 ± 1.0 4 0
SVG MESHED Jump 104) 73 ± 56.2 1.6 ± 0.4 9 1
TOTAL 36 35 1
Right Coronary System
SVG UNMESHED Single 2 67 ± 20.5 1.25 ± 0.7 2 0
Jump 15) 58 2 1 0
SVG MESHED Single 10 41 ± 28.1 1.5 ± 0.8 6 4
Jump 16) 78 2 1 0
Total 14 10 4
TTFM: Transit time flow-measurement, LIMA: Left internal mammary artery, RIMA: Right internal mammary artery, Radial A. : Left radial artery, SVG: Saphenous vein
graft, 1) 5) and 6) All single jump with 2 distal anastomoses, 2) RIMA as a free graft single jump with 2 distal anastomoses (n = 2), 3) Single jump with 2 distal
anastomoses (n = 4) and double jump with 3 distal anastomoses (n = 1), 4) Single jump with 2 distal anastomoses (n = 9) and double jump with 3 distal anastomoses
(n = 1), 6) Single jump with 2 distal anastomoses (n = 1)
Table 3 Venous graft quality, mesh-size, surgery, transit time flow measurement (TTFM), coronary status in occluded grafts (n = 5)
Graft No. 1 2 3 4 5
Graft - Target Coronary Vessel V-RIVP V-RIVP V-RCA V-RCA V-D-(M)
SVG Harvest technique (Endoscopic:
E, Open: O)
E E O E E
SVG Harvest site (magna: m, parva: p) m m p m m
SVG Varicosis1) Yes Yes No No Yes
SVG Quality2) Moderate Poor Poor Poor Moderate
SVG Mesh size (mm) 3.5 4.0 4.5 4.0 4.0
Perfusion: OPCAB, ECC, MECC OPCAB MECC ECC OPCAB ECC
Aorta: Clamping3) (C), Heartstring (H) C C C H C
Native Coronary run-off Poor: Calcified Moderate Poor: Calcified Moderate Moderate
Redo Proximal anastomosis (n) 0 0 0 0 0
Redo Distal anastomosis (n) 0 0 0 0 0
TTFM: Flow (ml/min) 47 21 30 15 214
TTFM: Pulsatility index 1.2 0.9 0.8 1.0 1.3
V- : « Veingraft to… », RIVP: Ramus interventricularis posterior, RCA: Right coronary artery, D: Ramus diagonalis, M: Ramus marginalis, SVG: Saphenous vein graft,
E: Endoscopic saphenous vein harvesting, O: Open saphenous vein harvesting, m: Vena saphena magna, p: Vena saphena parva, C: Anterior tangential
sideclamping of the ascending aorta, H: HEARTSTRING III Proximal Seal System (Maquet, Holding B.V. & Co. KG., Gossau, Switzerland), TTFM: Transit time
flow-measurement, 1) Signs of varicosis such as blow-outs, focally thinned out vein graft wall, dilated veingraft > 4.5 mm over > 1/3 of graft length, 2) Vein graft
quality according to presence of side branch tears, wall thickness, signs of varicosis such as blow-outs, thinned out vein graft wall and dilated graft > 4.5 mm
diameter over > 1/3 of graft length, 3) Partial side clamping of the ascending aorta
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evaluated by intra-operative TTFM after re-uptake of
cardiac function and post extracorporeal circulation.
Intra-operative complications such as technical meshing
problems or the necessity for redo of anastomoses were
recorded.
All patients were transferred to the intensive care unit
(ICU) and to the ward subsequently. They all received
Aspirin and a statin postoperatively.
Clinical and cCTA 1-year follow-up and major adverse
cerebral and cardiovascular events (MACCE)
In-hospital-follow-up continued until discharge for car-
diac rehabilitation and included days on ICU/ward and
MACCE ((mortality cardiac, non-cardiac), myocardial
infarction, stroke, major bleeding requiring surgical revi-
sion, new onset kidney injury and major vascular
complication).
Patients alive returned for clinical assessment and
cCTA one year (12 ± 0.1 months) after surgery. cCTA
was given preference to coronary angiography due to lower
radiation exposure, avoiding short-term hospitalization and
comparable sensitivity and specificity with regards to graft
patency detection [10, 11]. Major principal endpoint was
meshed graft patency in the cCTA. Secondary endpoints
were symptoms (dyspnea, angina pectoris). Furthermore,
potential predictors for meshed SVG occlusion were statis-
tically evaluated.
Data management and statistical analysis
Data were prospectively collected and analysed post-hoc
by an independent statistician. Continuous variables are
given as mean and standard deviation, categorical vari-
ables as numbers (n) and proportions (%). For the
descriptive statistics Fisher’s exact test was used for the
categorical variables – considering the small number -
and T-tests for the continuous variables followed by a
non-parametric analysis (Median test). All p values are
two-sided and p < 0.05 was considered statistically
significant. Analyses have been performed using SPSS 21
(IBM).
Ethical considerations
The study was approved by the local Independent Ethics
Committee and conducted according to Good Clinical
Practice (International Conference on Harmonisation)
and to the Declaration of Helsinki.
All authors had unlimited access to the complete data
set and take responsibility for its integrity. All authors
have read and agreed to the manuscript as written.
Results
Patients and baseline characteristics
A total of 22 patients received an eSVS® mesh from 06/
2010 to 06/2011 (with subsequent one-year cCTA in 19
patients). The eSVS® mesh implantation was successful
in all patients. Patients’ baseline characteristics are
shown in Table 1.
Excluded patients
Three patients died prior to 1-year follow-up control
and hence were excluded from analysis.
Patient 1 had off-pump revascularisation (sequential
LIMA to diagonal branch and LAD, unmeshed sequen-
tial SVG to marginal branch I and II, meshed SVG to
posterior descending artery (PDA)). On ICU the patient
was resuscitated due to sudden pulseless electrical activ-
ity (PEA) and had its chest reopened. Though initially
stabilized by means of extracorporeal membrane oxy-
genation (ECMO) the patient finally died due to biven-
tricular heart failure. A device related cardiac failure was
excluded by TTFM which revealed excellent flows in all
bypass grafts. Patient 2 was revascularized with MECC
support (LIMA to LAD, meshed SVG to PDA, unmeshed
sequential SVG to diagonal and marginal branches I and
II). Cause of death is unknown, however autopsy revealed
patent bypass grafts. Patient 3 was revascularized with
ECC support (RIMA to right coronary artery (RCA), me-
shed sequential SVG to intermediate and marginal
branches) and mechanical valve replacement. The Patient
died 1 year after surgery due to a myelodysplastic syn-
drome and subsequent sepsis.
Surgery
Perfusion technique and time of surgery/crossclamping
are given in Table 1. Every patient received a meshed
SVG. All meshes were deployed safely and implantation
was uneventful in all patients. Subsequent intra-
operative TTFM revealed an unrestricted patency with
good graft flows (59.8 ± 46.7 ml/min) and pulsatility in-
dices (1.6 ± 0.6) in all meshed grafts. Implanted mesh
sizes were 3.5 mm (n = 3), 4.0 mm (n = 13) and 4.5 mm
(n = 3). There was no intra-operative complication.
Graft patency and clinical follow-up
There was no directly device-related postoperative com-
plication. One patient developed a stroke with parapar-
esis with complete remission until discharge. No other
MACCE was recorded (excluding one non device-
related cardiac in-hospital and two non-device related
non-cardiac post-discharge deaths: excluded prior to
analysis).
Grafts and target coronary vessels, number of single
and sequential distal anastomoses, TTFM flows and pul-
satility indices as well as 1-year cCTA graft patency are
grouped and summarized in Table 2 for the right and
left coronary system, separately. 2.6 ± 0.5 grafts respect-
ively 3.7 ± 0.8 anastomoses were performed per patient.
All arterial and unmeshed SVGs were patent in 1-year
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cCTA. Among the eSVS® supported SVGs four with a
single distal anastomosis to the right coronary system
were completely occluded and one sequential graft with
two distal anastomoses to the left coronary system was
partially occluded between the proximal and first distal
anastomosis. The overall patency of distal anastomoses
was 85 % (n = 28/33) and overall graft patency was 76 %
(n = 16/21). At 1-year follow-up all patients were
asymptomatic.
Risk analysis for graft occlusion
Details of occluded grafts (n = 5) are listed in Table 3
and risk evaluation of potential risk factors for meshed
graft occlusion are shown in Table 4. Briefly, the intraop-
erative pulsatility index (PI) evaluated by TTFM had a
significant impact on postoperative graft occlusion. PI in
occluded grafts (1.0 ± 0.2) had been significantly lower
than in non-occluded grafts (1.7 ± 0.6). Furthermore,
poor vein quality (no better arterial or venous grafts
available) was almost a significant factor related to me-
shed graft occlusion. No other risk factor for meshed
SVG occlusion reached statistical significance despite a
predilection for the right coronary system (n = 4/5).
Discussion
One year after a safe implant of 19 eSVS® meshes with-
out intra- or postoperative device-related complications
all patients were asymptomatic and 76 %/85 % of grafts/
anastomoses were patent. Including off- and on-pump,
sequential as well as right and left sided revascularisa-
tion we found a prescriptive predilection for meshed
graft occlusion to the right coronary, in poor SVG qual-
ity and coronary run-off.
The overall patency rate of SVGs is inferior to arterial
grafts [1]. Early SVG occlusion occurs due to thrombosis
in up to 12 % already within the first six postoperative
months and graft patency is affected by narrowing in-
timal hyperplasia and subsequent atherosclerosis [2, 12].
Therefore, a rising concern for arterial revascularisation
has substantially influenced the current guidelines [4].
Nevertheless, SVGs are still essential in absent suitable
arterial conduits if they are the only available graft ma-
terial. In coronary stenoses < 90 % they are even
Table 4 Evaluation of Potential Risk Factors for eSVS® mesh supported saphenous vein grafts
Risk Factor Patent Occluded P-Value
Gender (n; %; male) 11 (68.8) 5 (31.3) 1.00
Age (years; mean ± std) 72.4 ± 8.2 65 ± 11.8 0.14
CAD in 1° relative (n; %) 13 (76.5) 4 (23.5) 0.47
Arterial hypertension (n; %) 14 (77.8) 4 (22.2) 0.26
Diabetes (n; %) 7 (87.5) 1 (12.5) 0.34
Dyslipidemia (n; %) 12 (75) 4 (25) 0.62
Smoking (n; %; current/former/never) 2(100)/10(76.9)/2 (50) 0 / 3 (23.1)/2 (50) 0.56
Previous myocardial infarction (n;%) 9 (69.2) 4 (30.8) 1.00
LVEF (%; mean ± std) 50.8 ± 12.9 44.8 ± 5 0.13
SVG Harvest technique: endoscopic 13 (76.5) 4 (23.5) 0.47
(n; %)
SVG Harvest site : magna (n; %) 13 (76.5) 4 (23.5) 0.47
SVG Varicosis (n; %) 9 (75) 3 (25) 1.00
SVG Quality 1 (25)/10 (83.3)/3 (100) 3 (75)/2 (16.7)/0 0.06
(n; %; poor/moderate/good)
Mesh size (n; %; 3.5 mm/4.0 mm/4.5 mm)1) 3 (75)/9 (75)/2 (66.7) 1 (25) / 3 (25)/1 (33.3) 1.00
Perfusion (n; %; OPCAB/ECC/MECC) 9 (81.8)/3 (60)/2 (66.7) 2 (18.2)/2 (40)/1 (33.3) 0.79
Aorta (n; %; Clamping/Heartstring) 4 (50)/9 (90) 4 (50)/1 (10) 0.16
Coronary system (n; %; left/right) 7 (87.5)/7 (63.6) 1 (12.5)/4 (36.4) 0.34
Coronary run-off (n; %; poor/moderate/good)2) 1(33.3)/9 (75)/4 (100) 2 (66.7)/3 (25)/0 0.12
Jumping graft (n; %) 8 (88.9) 1 (11.1) 0.30
TTFM: Flow (ml/min; mean ± std) 57.8 ± 28.9 64.4 ± 83.9 0.30
TTFM: Pulsatility index (mean ± std) 1.7 ± 0.6 1.0 ± 0.2 0.03
CAD: Coronary arterial disease, LVEF: Left ventricular ejection fraction, SVG: Saphenous vein graft, OPCAB: Off-pump coronary artery bypass, ECC: Extracorporeal
circulation, MECC: Minimal extracorporeal circulation, 1) Diameter, 2) For definition of run-off see “methods” section, TTFM: Transit time flow measurement
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favourable to arteries as arterial spasms and a high con-
curring coronary flow might lead to early graft occlusion
[3, 4]. The eSVS® mesh externally reinforces SVGs to re-
duce circumferential stress subsequently leading to
endothelial damage favouring SVG disease [2]. Hence it
should conceptionally improve SVG patency.
First animal eSVS® mesh implants demonstrated this
preventive effect on early (12 weeks) intimal hyperplasia
in primates. Schoettler, Genoni and Klima et al. pub-
lished first in human short and intermediate-term pa-
tency rates [6–8, 13]. Schoettler et al. state a detrimental
27.8 % nine-months-patency-rate in meshed against
85.7 % in non-meshed SVGs and substantially ques-
tioned the safety of the eSVS® device [13]. Subsiding re-
sults of Genoni et al. with a 95 % and Klima et al. with a
92 % eSVS® patency rate disproved Schoettler’s findings
[7, 8]. An evident technical implant difference of Schoet-
tler was the lack of forming a cobrahead at the anasto-
moses leading to a steep angulation comprising the flow
across the anastomosis as discussed by Genoni et al. and
by us in a short communication [7, 9]. As Emery et al. fi-
nally emphasized the importance of forming a cobrahead
all our patients were grafted with a cobrahead [5]. Our
patency rate of 76 %/85 % (of grafts/anastomoses) is
comparable to the literature of unmeshed SVGs despite
our 100 % patency of untreated SVGs [1, 14]. On the
other hand our meshed SVG patency seems slightly in-
ferior to Genoni’s and Klima’s findings [7, 8]. However,
relevant differences in the time-span until follow-up,
surgical setup, revascularized coronary targets and the
use of sequential anastomoses impedes a direct compar-
ability of these cited papers. Genoni et al. present very
short-term results 5 days after surgery without any fur-
ther published follow-up and focusses exclusively on the
right sided and off-pump revascularisation [7]. The cor-
onary run-off (calcification, vessel diameter) is not men-
tioned which is a known predictive factor for SVG
patency [1]. Klima et al. operated only on-pump omit-
ting sequential anastomoses and presents a relatively
smaller patient number (n = 12) assessed by cCTA [8].
Klima’s follow-up with 12 out of 21 patients (57.1 %) is
relatively low and cCTA control was performed within a
variable time-span of 3 to 14 months after surgery. In
contrast, the present study comprises various revasculari-
sation techniques (OPCAB, ECC and MECC), includes
single and sequential distal anastomoses to both sided cor-
onary targets, respects the SVG quality and coronary run-
off, presents the longest cCTA follow-up (12 ± 0.1 months)
and encompasses a larger patient collective with a more
comprehensive follow-up than Klima et al. [8].
The risk evaluation of the present study adds to the
value (Table 4) and statistical analysis was performed
with regards to the relatively small patient number. No
cardiovascular risk factor (arterial hypertension, diabetes,
CAD in 1° relative, etc.) revealed a significant difference
in meshed and unmeshed SVG occlusion suggesting a
safe application of the eSVS® mesh irrespectively of the
patient’s cardiovascular risk profile. Neither the harvest
technique nor site significantly influenced meshed SVG
occlusion. Although Lopez et al. questioned safety of
endoscopic vein harvesting recent studies prove its
uncompromised safety in the hands of experienced sur-
geons [15, 16]. Our high portion of sequential meshed
anastomoses confidently ruled out a negative impact on
meshed SVG patency. Basically, the peripheral coronary
resistance decreases with the number of sequential anas-
tomoses and a better graft flow decreases the risk for
graft occlusion. Klima et al. excluded sequentials
whereas Genoni et al. did not [7, 8]. We found one me-
shed SVG partially occluded between the proximal and
the first sequential distal anastomosis. As the distal graft
was patent we assume a problem at the proximal
anastomosis reinforcing the safe use of sequential me-
shed revascularisation. A non- significant predilection
of meshed SVG occlusion to the right coronary sys-
tem (n = 4/5) was observed. Despite an excellent
patency-rate exclusively to the right coronary system
a direct comparison of Genoni’s data is delicate con-
sidering the shorter postoperative follow-up of 5 days
and no comparable data of the left sided revasculari-
sation and the coronary run-off [7]. Both Goldmann
and Hess et al. evaluated a compromised coronary
run-off as well as a right coronary target as signifi-
cant risk factors for early SVG occlusion [1, 17].
Goldmann et al. even found similar right sided occlu-
sion rates (around 80 % after 1 year) relativating our
findings and supporting the theory that predilection
to the right side occured despite the lack of statistical
significance. The pulsatility index by TTFM reached
statistical significance (Table 4 : p = 0.03) whereas the
flow measure did not. Une et al. associated a TTFM
flow < 31 ml/min with significantly worse one-year
SVG patency than higher flows in CABG [18]. The
adequacy of intraoperative TTFM in meshed SVGs
was published by Emery et al. [19]. However, our
conflicting association of a low PI and graft occlusion
questions its predictive value. Furthermore, the use of
fibrin sealant and the technique of meshing the entire
SVG might be causative for meshed graft occlusion,
too. Emery et al. recommends a preferably thin exter-
nal layer of fibrin sealant to reliably fix the mesh on
the SVG [5]. This seems essential at the anastomoses
as the loops of the nitinol mesh are partially opened
when cutting the meshed graft to its appropriate
length. Hereby, open loops can easily get to lie intra-
luminally with a subsequent thrombogenic effect lead-
ing to graft occlusion. Despite this protective impact
the direct effect of fibrin sealant on meshed SVG
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patency remains unclear. Therefore, other devices
such as VEST (Venous External Scaffolding Tech-
nique, Vascular Graft Solutions Ltd., Tel Aviv, Israel)
suggest a mesh-free SVG at the site of anastomosis.
The main limiting factor of this study is the relatively
low number of patients. Hence a careful interpretation
of the data is mandatory although it was considered in
the statistical analysis. An adequate follow-up and pa-
tient volume, safe sequential off- and on-pump left and
right sided revascularisation reinforce this study towards
the background of the current state of recent literature.
Conclusions
In conclusion we safely implanted 19 eSVS® meshes
without directly device-related complications with an
overall one-year SVGs/anastomoses patency-rate of
76 %/85 % comparable to the literature of meshed and
non-meshed SVGs. Neither cardiovascular risk profile,
revascularisation technique, vein harvest site and tech-
nique, coronary target side and run-off nor sequential or
single distal anastomoses were significant predictive fac-
tors for graft occlusion. On the other hand, descriptive
predilection of the right coronary system, vein varicosis
and poor coronary run-off can serve as soft indicators
for early graft occlusion in eSVS® supported vein grafts.
However, graft patency of meshed veins (76 %) was in-
ferior to non-meshed (100 %) or arterial grafts (100 %).
Thus our mid-term data do not sustain the concept of
improving vein graft patency by external reinforcing
with the eSVS® mesh. Further long-term follow-up is
warranted.
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